Zonisamide (Zonegran) News, Updated Regularly

Update on Antiepileptic Drug (AED) Treatment for Epilepsy - Medscape News
November 4, 2008, 6:48 pm

Several recent studies have compared older and newer AEDs for initial treatment of partial-onset and generalized epilepsy. The large SANAD study, for example, recently showed that treatment retention for patients receiving initial treatment for ...

Parkinson's Disease Market Upgrade Following Evidence of Disease ... - PR Inside
October 16, 2008, 2:41 pm

www.researchandmarkets.com - Research and Markets ( www.researchandmarkets.com/research/c84a4e/forecast_insight ) has announced the addition of the "Forecast Insight: Parkinson's Disease - Market Upgrade following Evidence of Disease Slowing with ...

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation ... - Yahoo Finance
October 6, 2008, 5:42 am

- Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with Better Tolerability in Clinical Trials - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX - News ), a biopharmaceutical company focused on ...

Orexigen Therapeutics Announces Multiple Data Presentations at The ... - PR Newswire
September 29, 2008, 8:28 am

SAN DIEGO, Sept 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced its active calendar of ...

Orexigen(R) Therapeutics Reviews Significant Data Regarding Its ... - PR Newswire
October 7, 2008, 5:48 am

PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (NASDAQ: OREX) , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced that the company reviewed in an ...

Elan Reports Third Quarter 2008 Financial Results - StreetInsider.com
October 22, 2008, 11:45 pm

Elan Corporation, plc today announced its third quarter 2008 financial results and provided a business update. Commenting on Elan's business, Kelly Martin, Elan's president and chief executive officer, said, "This quarter's results demonstrate ...

Are you looking for additional Zonegran (Zonisamide) news? Try our new "Zonisamide News Focus" area.

Are you looking for additional Zonegran (Zonisamide) information? Try our new "Zonisamide Related Blog Entries" area.

Off-site Zonisamide (Zonegran) Links, User Submitted

The following links have been collected through user bookmark submission in the Zonisamide_Zonegran category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Thu Sep 18

• Zonisamide - Wikipedia, the free encyclopedia

Mon Mar 17

• Zonisamide - Yahoo! Health: What are the possible side effects of zonisamide? Get emergency medical help if you have any of these signs of an allergic reaction: any form of skin rash; hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
• Zonisamide - Wikipedia, the free encyclopedia: Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures.
• MedlinePlus Drug Information: Zonisamide: Zonisamide is used in combination with other medications to treat seizures in adults with epilepsy. Zonisamide is in a class of medications called anticonvulsant s. It works by decreasing abnormal excitement in the brain.
• Zonisamide (Oral Route) - MayoClinic.com: US Brand Names * Zonegran Description Zonisamide is used to control some kinds of seizures in the treatment of epilepsy. This medicine is available only with your doctor's prescription. This product is available in the following dosage forms:

Wed Sep 19

• Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study: In this short-term, open-label, preliminary trial, combination treatment of zonisamide and bupropion resulted in more weight loss than treatment with zonisamide alone.
• JAMA -- Zonisamide for Weight Loss in Obese Adults: A Randomized Controlled Trial, April 9, 2003, Gadde et al. 289 (14): 1820: In this short-term, preliminary trial, zonisamide and hypocaloric diet resulted in more weight loss than placebo and hypocaloric diet in the treatment of obesity.

Sat Mar 10

• Smoldering Myeloma Associated with Zonisamide Treatment: When zonisamide is used, the monitoring of serum levels of M-protein and patterns of gammaglobulin is warranted.

Off-site Zonisamide Research Links

If you still need additional information on Zonisamide then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.